search
Back to results

Safety of Various Mode of Delivery of Iron Supplement on Iron Toxicity Markers in Preschool Children

Primary Purpose

Iron Overload, Oxidative Stress

Status
Unknown status
Phase
Phase 3
Locations
India
Study Type
Interventional
Intervention
Iron Supplementation
Sponsored by
Annamalai University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Iron Overload focused on measuring iron, iron toxicity markers, oxidative stress markers, iron supplementation, NTBI, iron over load, interleukin levels, iron status, acut phase reactants, preschool children

Eligibility Criteria

24 Months - 36 Months (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • between 24-36 months of age
  • not severely malnourished or ill requiring hospitalization
  • willing to stay in the study area for 6 months
  • consent to participate

Exclusion Criteria:

  • not consented
  • severely malnourished or ill requiring hospitalization

Sites / Locations

  • Center for Micronutrient Research

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Placebo Comparator

Arm Label

IT

IZ

IB

CO

Arm Description

Iron Tablet group (12.5 mg/d) + Placebo Biscuit

Iron (12.5mg/d)+Zinc (10 mg/d) Tablet Group + Placebo Biscuit

Iron Fortified Biscuit Group(12.5 mg/d)+ Placebo Tablet

Placebo Tablet + Placebo Biscuit

Outcomes

Primary Outcome Measures

The effect of intervention on immune response, iron over load, oxidative stress markers and iron status

Secondary Outcome Measures

Primary Outcome Measures: Mortality Incidence of disease requiring hospitalization interleukin response during severe illness or hospitalization

Full Information

First Posted
September 18, 2009
Last Updated
September 18, 2009
Sponsor
Annamalai University
search

1. Study Identification

Unique Protocol Identification Number
NCT00980421
Brief Title
Safety of Various Mode of Delivery of Iron Supplement on Iron Toxicity Markers in Preschool Children
Official Title
Effect of Mode of Delivery of Iron and/or Iron and Zinc Supplement on Iron Status Markers and Potential Markers of Iron Toxicity in Children Aged 24-36 Months
Study Type
Interventional

2. Study Status

Record Verification Date
September 2009
Overall Recruitment Status
Unknown status
Study Start Date
October 2009 (undefined)
Primary Completion Date
August 2010 (Anticipated)
Study Completion Date
August 2010 (Anticipated)

3. Sponsor/Collaborators

Name of the Sponsor
Annamalai University

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of study is to evaluate and compare the effect of iron supplementation when given as iron tablet or fortified biscuit or combined with zinc in the form of tablet on morbidity and iron toxicity markers among children aged 24-36 months.
Detailed Description
The study will be carried out in two phases in Sangam Vihar, Delhi. The survey will be conducted to identify children in the age group of 24-36 months. After obtaining consent, an enrollment form with detailed socio-demographic information about the child will be filled. Blood and urine samples will be collected for estimation of iron status, oxidative stress, immune and interleukin markers. Based on iron status, two randomization lists will be generated i.e. one for iron sufficient and other for iron deficient children. Children will be randomly allocated to receive one of the four interventions (60 in each group) for 180 days. The intervention will be either Iron Tablets (IT) or Iron and Zinc tablets (IZ) or Biscuits fortified with Iron (IB), or Placebo tablets (CO). Children in the iron groups (IT and IB) will receive 12.5 mg/day of iron. Children allocated to receive Iron and Zinc (IZ group) will receive 10 mg/day of Zinc in addition to 12.5 mg/day of Iron. The fortified biscuits (IB) will be formulated by CFTRI, Mysore, India and will have iron in the form of iron sulphate. The iron (IT group) or iron and zinc (IZ group) fortified dispersible tablets will be procured from WHO manufactured by Nutriset (Maluanlay, France). Tablets will have iron salt in the form of ferrous sulphate and zinc in the form of zinc sulphate. The interventions at the baseline on Day 3, on Day 30 (on completion of Phase -I) and on Day 180 (on completion of Phase-II) will be given at the clinic prior to the post 3 hour blood collection. Regular supplementation will be given at home. Children will be followed up on a biweekly basis by the field worker for delivery of the intervention, collection of morbidity and compliance information from the mother/caretaker of the child. During follow-up, blood sample for interleukin levels will be taken in the event of an illness such as diarrhea, pneumonia, fever and severe illness/hospitalization. At the completion of Phase-I (on day 30) and Phase - II (on day 180), the blood and urine samples will be collected again for estimation of iron status, oxidative stress, immune and interleukin markers.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Iron Overload, Oxidative Stress
Keywords
iron, iron toxicity markers, oxidative stress markers, iron supplementation, NTBI, iron over load, interleukin levels, iron status, acut phase reactants, preschool children

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
240 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
IT
Arm Type
Experimental
Arm Description
Iron Tablet group (12.5 mg/d) + Placebo Biscuit
Arm Title
IZ
Arm Type
Experimental
Arm Description
Iron (12.5mg/d)+Zinc (10 mg/d) Tablet Group + Placebo Biscuit
Arm Title
IB
Arm Type
Experimental
Arm Description
Iron Fortified Biscuit Group(12.5 mg/d)+ Placebo Tablet
Arm Title
CO
Arm Type
Placebo Comparator
Arm Description
Placebo Tablet + Placebo Biscuit
Intervention Type
Dietary Supplement
Intervention Name(s)
Iron Supplementation
Other Intervention Name(s)
Ferrous sulphate
Intervention Description
Iron tablet group (12.5 mg/d)+ Placebo Biscuit;Iron(12.5 mg/d)+ Zinc (10 mg/d) tablet group+ Placebo Biscuit; Iron Fortified Biscuit Group (12.5 mg/d)+ Placebo Tablet; Placebo tablet +Placebo Biscuit
Primary Outcome Measure Information:
Title
The effect of intervention on immune response, iron over load, oxidative stress markers and iron status
Time Frame
0 month, 1 month and 6 months
Secondary Outcome Measure Information:
Title
Primary Outcome Measures: Mortality Incidence of disease requiring hospitalization interleukin response during severe illness or hospitalization
Time Frame
180 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
24 Months
Maximum Age & Unit of Time
36 Months
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: between 24-36 months of age not severely malnourished or ill requiring hospitalization willing to stay in the study area for 6 months consent to participate Exclusion Criteria: not consented severely malnourished or ill requiring hospitalization
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Venugopal P Menon, PhD
Phone
91-4144-238343
Email
biocmr@sify.com
First Name & Middle Initial & Last Name or Official Title & Degree
Jitender Kumar, PhD
Phone
91-41724901
Email
cmrdelhi@airtelmail.in
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Venugopal P Menon, PhD
Organizational Affiliation
Annamalai University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Center for Micronutrient Research
City
Delhi
ZIP/Postal Code
110024
Country
India
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Venugopal P Menon, PhD
Phone
91-4144-238343
Email
biocmr@sify.com
First Name & Middle Initial & Last Name & Degree
Jitendra Kumar, PhD
Phone
91-41724901
Email
cmrdelhi@airtelmail.in
First Name & Middle Initial & Last Name & Degree
Venugopal P Menon, PhD

12. IPD Sharing Statement

Citations:
PubMed Identifier
15864409
Citation
Hoppe M, Hulthen L, Hallberg L. The relative bioavailability in humans of elemental iron powders for use in food fortification. Eur J Nutr. 2006 Feb;45(1):37-44. doi: 10.1007/s00394-005-0560-0. Epub 2005 Apr 25.
Results Reference
background
PubMed Identifier
11354283
Citation
Olynyk JK, Clarke SL. Iron overload impairs pro-inflammatory cytokine responses by Kupffer cells. J Gastroenterol Hepatol. 2001 Apr;16(4):438-44. doi: 10.1046/j.1440-1746.2001.02456.x.
Results Reference
background

Learn more about this trial

Safety of Various Mode of Delivery of Iron Supplement on Iron Toxicity Markers in Preschool Children

We'll reach out to this number within 24 hrs